Unknown

Dataset Information

0

The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.


ABSTRACT: Despite new treatment modalities, the clinical outcome in a substantial number of patients with multiple myeloma (MM) has yet to be improved. Antibody-based targeted therapies for myeloma patients could make use of the HM1.24 antigen (CD317), a surface molecule overexpressed on malignant plasma cells and efficiently internalized. Here, a novel immunotoxin, HM1.24-ETA', is described. HM1.24-ETA' was generated by genetic fusion of a CD317-specific single-chain Fv (scFv) antibody and a truncated variant of Pseudomonas aeruginosa exotoxin A (ETA'). HM1.24-ETA' inhibited growth of interleukin 6 (IL-6)-dependent and -independent myeloma cell lines. Half-maximal growth inhibition was observed at concentrations as low as 0.3?nM. Target cell killing occurred via induction of apoptosis and was unaffected in co-culture experiments with bone marrow stromal cells. HM1.24-ETA' efficiently triggered apoptosis of freshly isolated/cryopreserved cells of patients with plasma cell leukemia and MM and was active in a preclinical severe combined immunodeficiency (SCID) mouse xenograft model. Importantly, HM1.24-ETA' was not cytotoxic against CD317-positive cells from healthy tissue (monocytes, human umbilical vein endothelial cells). These results indicate that CD317 may represent a promising target structure for specific and efficient immunotoxin therapy for patients with plasma cell tumors.

SUBMITTER: Staudinger M 

PROVIDER: S-EPMC4080209 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.

Staudinger M M   Glorius P P   Burger R R   Kellner C C   Klausz K K   Günther A A   Repp R R   Klapper W W   Gramatzki M M   Peipp M M  

Blood cancer journal 20140613


Despite new treatment modalities, the clinical outcome in a substantial number of patients with multiple myeloma (MM) has yet to be improved. Antibody-based targeted therapies for myeloma patients could make use of the HM1.24 antigen (CD317), a surface molecule overexpressed on malignant plasma cells and efficiently internalized. Here, a novel immunotoxin, HM1.24-ETA', is described. HM1.24-ETA' was generated by genetic fusion of a CD317-specific single-chain Fv (scFv) antibody and a truncated va  ...[more]

Similar Datasets

| S-EPMC6778635 | biostudies-literature
| S-EPMC5341994 | biostudies-literature
| S-EPMC5689652 | biostudies-literature
| S-EPMC3729839 | biostudies-literature
| S-EPMC8225673 | biostudies-literature
| S-EPMC10952688 | biostudies-literature
| S-EPMC5794718 | biostudies-literature
| S-EPMC5652688 | biostudies-literature
| S-EPMC7435071 | biostudies-literature
| S-EPMC6774835 | biostudies-literature